Cargando…

Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma

Recently, Brentuximab Vedotin (BV) has emerged as an important therapy not only for Hodgkin’s Lymphoma, but also for CD30-positive T cell lymphomas. Although anemia and thrombocytopenia are common myelosuppressive side effects, to our knowledge, this is the first described case of Evans Syndrome ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Irimia, Ruxandra, Barbu, Sinziana, Popa, Codruta, Badelita, Sorina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048708/
https://www.ncbi.nlm.nih.gov/pubmed/36975736
http://dx.doi.org/10.3390/hematolrep15010023
_version_ 1785014263158407168
author Irimia, Ruxandra
Barbu, Sinziana
Popa, Codruta
Badelita, Sorina
author_facet Irimia, Ruxandra
Barbu, Sinziana
Popa, Codruta
Badelita, Sorina
author_sort Irimia, Ruxandra
collection PubMed
description Recently, Brentuximab Vedotin (BV) has emerged as an important therapy not only for Hodgkin’s Lymphoma, but also for CD30-positive T cell lymphomas. Although anemia and thrombocytopenia are common myelosuppressive side effects, to our knowledge, this is the first described case of Evans Syndrome associated with BV therapy. We present the case of a 64-year-old female, diagnosed with relapsed Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL-NOS), who, after receiving six cycles of BV, developed authentic severe autoimmune hemolytic anemia with strong positive direct anti-globulin (Coombs) test, simultaneously associated with severe immune thrombocytopenia. The patient was unresponsive to systemic corticotherapy, but fully recovered after a course of IV immunoglobulin.
format Online
Article
Text
id pubmed-10048708
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100487082023-03-29 Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma Irimia, Ruxandra Barbu, Sinziana Popa, Codruta Badelita, Sorina Hematol Rep Case Report Recently, Brentuximab Vedotin (BV) has emerged as an important therapy not only for Hodgkin’s Lymphoma, but also for CD30-positive T cell lymphomas. Although anemia and thrombocytopenia are common myelosuppressive side effects, to our knowledge, this is the first described case of Evans Syndrome associated with BV therapy. We present the case of a 64-year-old female, diagnosed with relapsed Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL-NOS), who, after receiving six cycles of BV, developed authentic severe autoimmune hemolytic anemia with strong positive direct anti-globulin (Coombs) test, simultaneously associated with severe immune thrombocytopenia. The patient was unresponsive to systemic corticotherapy, but fully recovered after a course of IV immunoglobulin. MDPI 2023-03-22 /pmc/articles/PMC10048708/ /pubmed/36975736 http://dx.doi.org/10.3390/hematolrep15010023 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Irimia, Ruxandra
Barbu, Sinziana
Popa, Codruta
Badelita, Sorina
Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma
title Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma
title_full Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma
title_fullStr Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma
title_full_unstemmed Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma
title_short Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma
title_sort evans syndrome as a possible complication of brentuximab vedotin therapy for peripheral t cell lymphoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10048708/
https://www.ncbi.nlm.nih.gov/pubmed/36975736
http://dx.doi.org/10.3390/hematolrep15010023
work_keys_str_mv AT irimiaruxandra evanssyndromeasapossiblecomplicationofbrentuximabvedotintherapyforperipheraltcelllymphoma
AT barbusinziana evanssyndromeasapossiblecomplicationofbrentuximabvedotintherapyforperipheraltcelllymphoma
AT popacodruta evanssyndromeasapossiblecomplicationofbrentuximabvedotintherapyforperipheraltcelllymphoma
AT badelitasorina evanssyndromeasapossiblecomplicationofbrentuximabvedotintherapyforperipheraltcelllymphoma